Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
NCT04074993
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER_GOV
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Brigatinib
Sponsor
JI-YOUN HAN
Collaborators
[object Object]
[object Object]
[object Object]